請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85361完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 翁德怡(Te-I Weng) | |
| dc.contributor.author | I-Ting Yang | en |
| dc.contributor.author | 楊依庭 | zh_TW |
| dc.date.accessioned | 2023-03-19T23:00:15Z | - |
| dc.date.copyright | 2022-10-03 | |
| dc.date.issued | 2022 | |
| dc.date.submitted | 2022-07-21 | |
| dc.identifier.citation | 1.Lexicon of alcohol and drug terms: World Health Organization, in Advocatetanmoy Law Library. 2020, World Health Organization. 2.Organization, W.H., Suicide worldwide in 2019. 2021, World Health Organization. 3.全國自殺死亡資料統計. 2021, 全國自殺防治中心. 4.Bachmann, S., Epidemiology of Suicide and the Psychiatric Perspective. Int J Environ Res Public Health, 2018. 15(7). 5.林俊宏, et al., 臺北市自殺企圖者之特徵. 北市醫學雜誌, 2006. 3(10): p. 1008-1016. 6.黃梓瑄, 難治型憂鬱症患者之自殺風險評估, in 醫務管理學系碩士班. 2021, 台北醫學大學. 7.田匯鋆, 臺灣農藥中毒自殺之特徵:全國死因檔案與北台灣一所醫學中心之病歷研究, in 公共衛生碩士學位學程. 2018, 國立臺灣大學. p. 1-46. 8.吳佳儀, et al., 多元性別族群之精神健康與自殺防治. 台灣醫學, 2021. 25(4): p. 522-530. 9.張奕涵, et al., 台灣自殺死亡率趨勢之改變:連結點迴歸分析(1971-2018年). 台灣公共衛生雜誌, 2020. 39(5): p. 536-552. 10.廖士程, et al., 台灣自殺防治十年回顧檢討與展望. 台灣公共衛生雜誌, 2015. 34(3): p. 227-239. 11.蘇美心, 探討人格特質、遺傳因子及保護因子對自殺行為之影響, in 流行病學與預防醫學研究所. 2020, 國立臺灣大學. p. 1-99. 12.Turecki, G., et al., Suicide and suicide risk. Nature Reviews Disease Primers, 2019. 5(1). 13.Di Giacomo, E., et al., Estimating the Risk of Attempted Suicide Among Sexual Minority Youths. JAMA Pediatrics, 2018. 172(12): p. 1145. 14.Hottes, T.S., et al., Lifetime Prevalence of Suicide Attempts Among Sexual Minority Adults by Study Sampling Strategies: A Systematic Review and Meta-Analysis. American Journal of Public Health, 2016. 106(5): p. e1-e12. 15.Na, E.J., et al., Risks of Completed Suicide of Community Individuals with ICD-10 Disorders Across Age Groups: A Nationwide Population-Based Nested Case-Control Study in South Korea. Psychiatry Investigation, 2019. 16(4): p. 314-324. 16.Lin, H.-T., et al., Insomnia as an independent predictor of suicide attempts: a nationwide population-based retrospective cohort study. BMC Psychiatry, 2018. 18(1). 17.Suicide, Newsroom, Editor. 2021, World Health Organization. 18.Azarbakhsh, H., et al., Epidemiology of Suicide by Medication Overdose: A Population–based Study 2011–2019. Archives of Medical Research, 2021. 19.Iorfino, F., Hermens, D. F., Cross, S. P. M., Zmicerevska, N., Nichles, A., Groot, J., Guastella, A. J. Scott, E. M., & Hickie, I. B., Prior suicide attempts predict worse clinical and functional outcomes inyoung people attending a mental health service. Journal of Affective Disorders, 2018. 238: p. 563-569. 20.Fagerström, C., et al., Life weariness, suicidal thoughts and mortality: a sixteen-year longitudinal study among men and women older than 60 years. BMC Public Health, 2021. 21(1). 21.Jokinen, J., et al., Life expectancy after the first suicide attempt. Acta Psychiatrica Scandinavica, 2018. 137(4): p. 287-295. 22.Daly, C., et al., Repeat Self-Harm Following Hospital-Presenting Intentional Drug Overdose among Young People—A National Registry Study. International Journal of Environmental Research and Public Health, 2020. 17(17): p. 6159. 23.Geith, S., et al., Lessons to be learned: identifying high-risk medication and circumstances in patients at risk for suicidal self-poisoning. International Journal of Mental Health Systems, 2022. 16(1). 24.Spiller, H.A., et al., Suicide attempts by self-poisoning in the United States among 10–25 year olds from 2000 to 2018: substances used, temporal changes and demographics. Clinical Toxicology, 2020. 58(7): p. 676-687. 25.McCall, W.V., et al., Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA. American Journal of Psychiatry, 2017. 174(1): p. 18-25. 26.Miller, T.R., et al., Incidence and Lethality of Suicidal Overdoses by Drug Class. JAMA Network Open, 2020. 3(3): p. e200607. 27.Zwald, M.L., Holland, K. M., Annor, F. B., Kite-Powell, A., Sumner, S. A., Bowen, D. A., Vivolo-Kantor, A. M., Stone, D. M., & Crosby, A. E., Syndromic Surveillance of Suicidal Ideation and Self-Directed Violence — United States, January 2017–December 2018. , H.a.H. Services, Editor. 2020, Centers for Disease Control and Prevention: United States. p. 103-108. 28.Web-based Injury Statistics Query and Reporting System (WISQARS). H.a.H. Services, Editor. 2019, Centers for disease contol: Atlanta, Georgia, United States. 29.Lee, J.S., et al., Changes in Diagnosis of Poisoning in Patients in the Emergency Room Using Systematic Toxicological Analysis with the National Forensic Service. Journal of Korean Medical Science, 2021. 36(18). 30.Baud, F.J. and P. Houzé, Chapter 30 - Introduction to clinical toxicology, in An Introduction to Interdisciplinary Toxicology, C.N. Pope and J. Liu, Editors. 2020, Academic Press. p. 413-428. 31.Jarrad, R.W., Chapter 32 - Introduction to forensic toxicology, in An Introduction to Interdisciplinary Toxicology, N.P. Carey and L. Jing, Editors. 2020, Academic Press. p. 445-459. 32.Dawling, S., Ward, N., Essex, E. G., & Widdop, B., Rapid measurement of basic drugs in blood applied to clinical and forensic toxicology. Annals of Clinical Biochemistry, 1990. 27: p. 473-477. 33.Dinis-Oliveira, R.J., D.N. Vieira, and T. Magalhães, Guidelines for Collection of Biological Samples for Clinical and Forensic Toxicological Analysis. Forensic Sciences Research, 2016. 1(1): p. 42-51. 34.Launiainen, T. and I. Ojanperä, Drug concentrations in post‐mortem femoral blood compared with therapeutic concentrations in plasma. Drug Testing and Analysis, 2014. 6(4): p. 308-316. 35.Avataneo, V., et al., Therapeutic drug monitoring‐guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence. British Journal of Clinical Pharmacology, 2018. 84(11): p. 2535-2543. 36.Banaszkiewicz, L., et al., Rapid and simple multi-analyte LC–MS/MS method for the determination of benzodiazepines and Z-hypnotic drugs in blood samples: Development, validation and application based on three years of toxicological analyses. Journal of Pharmaceutical and Biomedical Analysis, 2020. 191: p. 113569. 37.Campêlo, J.D.M., et al., Optimization of QuEChERS extraction for detection and quantification of 20 antidepressants in postmortem blood samples by LC-MS/MS. Forensic Science International, 2021. 319: p. 110660. 38.De Nicolò, A., et al., UHPLC–MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. Journal of Pharmaceutical and Biomedical Analysis, 2016. 129: p. 535-541. 39.Flint, R.B., et al., Quantification of Acetaminophen and Its Metabolites in Plasma Using UPLC-MS: Doors Open to Therapeutic Drug Monitoring in Special Patient Populations. Therapeutic Drug Monitoring, 2017. 39(2): p. 164-171. 40.Gundersen, P.O.M., et al., Quantification of 21 antihypertensive drugs in serum using UHPLC-MS/MS. Journal of Chromatography B, 2018. 1089: p. 84-93. 41.Haage, P., et al., Quantitation of the enantiomers of tramadol and its three main metabolites in human whole blood using LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2016. 119: p. 1-9. 42.Hairin, T., et al., Quantitative LC/MS/MS analysis of acetaminophen–cysteine adducts (APAP–CYS) and its application in acetaminophen overdose patients. Analytical Methods, 2013. 5(8): p. 1955. 43.Johannsen, J.-O., et al., Reliable and easy-to-use LC–MS/MS-method for simultaneous determination of the antihypertensives metoprolol, amlodipine, canrenone and hydrochlorothiazide in patients with therapy-refractory arterial hypertension. Journal of Pharmaceutical and Biomedical Analysis, 2019. 164: p. 373-381. 44.Kim, L., <Development_and_Validation_of_18 antidepressants.pdf>. 2019. 45.Lu, W., et al., Simultaneous determination of acetaminophen and oxycodone in human plasma by LC–MS/MS and its application to a pharmacokinetic study. Journal of Pharmaceutical Analysis, 2018. 8(3): p. 160-167. 46.Mahrouse, M.A., Simultaneous ultraperformance liquid chromatography/tandem mass spectrometry determination of four antihypertensive drugs in human plasma using hydrophilic-lipophilic balanced reversed-phase sorbents sample preparation protocol. Biomedical Chromatography, 2018. 32(12): p. e4362. 47.Ryan, T.P., et al., Medication adherence, medical record accuracy, and medication exposure in real-world patients using comprehensive medication monitoring. PLOS ONE, 2017. 12(9): p. e0185471. 48.Saar, E., et al., Identification and quantification of 30 antipsychotics in blood using LC-MS/MS. J Mass Spectrom, 2010. 45(8): p. 915-25. 49.Sempio, C., et al., Simple and sensitive screening and quantitative determination of 88 psychoactive drugs and their metabolites in blood through LC–MS/MS: Application on postmortem samples. Journal of Chromatography B, 2014. 970: p. 1-7. 50.Van Der Nagel, B.C.H., et al., High-throughput quantification of 8 antihypertensive drugs and active metabolites in human plasma using UPLC–MS/MS. Journal of Chromatography B, 2017. 1060: p. 367-373. 51.Verplaetse, R. and J. Tytgat, Development and validation of a sensitive UPLC–MS/MS method for the analysis of narcotic analgesics in urine and whole blood in forensic context. Forensic Science International, 2012. 215(1): p. 136-145. 52.Vignali, C., et al., Distribution of Fluvoxamine and Identification of the Main Metabolite in a Fatal Intoxication. Journal of Analytical Toxicology, 2021. 45(4): p. e1-e5. 53.Handbook of LC-MS bioanalysis: best practices, experimental protocols, and regulations. 2013, United States of America: John Wiley & Sons, Inc. 54.Gonzalez, O., et al., Development of an LC-MS/MS method for the quantitation of 55 compounds prescribed in combined cardiovascular therapy. J Chromatogr B Analyt Technol Biomed Life Sci, 2011. 879(3-4): p. 243-52. 55.Chen, J.-Y., et al., Development of an analytical method to detect simultaneously 219 new psychoactive substances and 65 other substances in urine specimens using LC-QqQ MS/MS with CriticalPairFinder and TransitionFinder. Talanta, 2022. 238: p. 122979. 56.2017 ICD-10-CM and GEMs. [cited 2022 5/21]; Available from: https://www.cms.gov/Medicare/Coding/ICD10/2017-ICD-10-CM-and-GEMs. 57.Kalankesh, L.R., et al., Exploring Complexity of Deliberate Self-Poisoning through Network Analysis. Psychiatry Journal, 2017. 2017: p. 1-11. 58.<Bioanalytical-Method-Validation-Guidance-for-Industry.pdf>, H.a.H. Services, Editor. 2018, U. S. Food and Drug Administration. 59.Wang, X., et al., Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography–tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2012. 70: p. 320-329. 60.Feng, S., O.T. Cummings, and G. McIntire, Zolpidem and Zolpidem Carboxylic Acid Results from Medication Monitoring. Journal of Analytical Toxicology, 2018. 42(7): p. 491-495. 61.Marin, S.J. and G.A. McMillin, LC-MS/MS Analysis of 13 Benzodiazepines and Metabolites in Urine, Serum, Plasma, and Meconium, in Clinical Applications of Mass Spectrometry: Methods and Protocols, U. Garg and C.A. Hammett-Stabler, Editors. 2010, Humana Press: Totowa, NJ. p. 89-105. 62.Marumo, A., et al., Analysis of Phenothiazines in Human Body Fluids Using Disk Solid-Phase Extraction and Liquid Chromatography. Journal of AOAC INTERNATIONAL, 2005. 88(6): p. 1655-1660. 63.Wang, L.-l., et al., Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. European Journal of Drug Metabolism and Pharmacokinetics, 2020. 45(4): p. 477-485. 64.Daniël, J., et al., The burden of intentional self-poisoning on a district-level public Hospital in Cape Town, South Africa. African Journal of Emergency Medicine, 2018. 8(3): p. 79-83. 65.Gharbaoui, M., et al., Pattern of suicide by self-poisoning in Northern Tunisia: An eleven-year study (2005-2015). J Forensic Leg Med, 2019. 61: p. 1-4. 66.Gonzalez-Urdiales, P., et al., Pediatric Intentional Self-poisoning Evaluated in the Emergency Department: An International Study. Pediatr Emerg Care, 2021. 37(12): p. e1631-e1636. 67.Karaca, O. and A. Ertaşkın, Epidemiology of Self-poisoning with Drug in the Central Anatolian Region in Turkey. Cureus, 2020. 12(2): p. e6962. 68.Boukhorb, S., Hadrya, F., Amiar, L., Hmimou, S., Soulaymani, A., Rhalem, N., Diallo, T., Mokhtari, A., Soulaymani-Bencheikh, R., Hami, H., Deliberate self-poisoning with drugs among adolescents in Morocco, in E3S Web of Conferences. 2021. p. 02004. 69.Makhtoomi, M. and S. Jafarnezhad, Prevalence of self-poisoning among patients referred and admitted to hospitals in Tonekabon and Ramsar from 2005 to 2015. Tabari Biomedical Student Research Journal, 2019. 1(3): p. 14-20. 70.Benedict, M., C. Van Loggerenberg, and W. Steinberg, The profile of deliberate self-poisoning cases presenting at the emergency department of Pelonomi Regional Hospital, Bloemfontein. South African Family Practice, 2019. 61(1): p. 11-17. 71.Hawton, K., et al., Psychiatric disorders in patients presenting to hospital following self-harm: A systematic review. Journal of Affective Disorders, 2013. 151(3): p. 821-830. 72.Pushpakumara, P.H.G.J., et al., Exploration of associations between deliberate self-poisoning and psychiatric disorders in rural Sri Lanka: A case-control study. PLOS ONE, 2021. 16(8): p. e0255805. 73.Hawkins, M., et al., Suicide deaths by intentional self-poisoning in people with cardiovascular disease. General Hospital Psychiatry, 2018. 52: p. 41-47. 74.Simmons, Z., et al., Insomnia symptom severity is associated with increased suicidality and death by suicide in a sample of patients with psychiatric disorders. Sleep, 2021. 44(7). 75.El-Farouny, R. and M. Helmy, SUICIDAL SELF POISONING AND ITS RELATION WITH PERSONALITY TRAITS AMONG ADMITTED CASES TO MENOUFIA POISONING CONTROL CENTER. The Egyptian Journal of Forensic Sciences and Applied Toxicology, 2021. 21(1): p. 13-30. 76.Vujaklija Brajković, A., et al., Self-poisoning as a cause of admission in a medical intensive care unit and a question of misuse of prescription medications. Heart & Lung, 2022. 51: p. 17-21. 77.Hori, S. and K. Kinoshita, Clinical characteristics of patients who overdose on multiple psychotropic drugs in Tokyo. The Journal of Toxicological Sciences, 2016. 41(6): p. 765-773. 78.Yasuda, M. and T. Kobayashi, Suicide attempts by drug overdose at Jichi Medical University Hospital emergency centre: A study of patient characteristics and quantity of drug overdose. Asian Journal of Psychiatry, 2019. 41: p. 34-37. 79.Schulz, M., Schmoldt, A., Andresen-Streichert, H., & Iwersen-Bergmann, S., Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. 2020(1466-609X (Electronic)). 80.Bruce, R.D., et al., Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone. The American Journal of Drug and Alcohol Abuse, 2011. 37(4): p. 224-228. 81.Hiemke, C., et al., Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 2018. 51(01/02): p. 9-62. 82.Greenblatt, D.J., et al., Clinical Pharmacokinetics of Lorazepam. IV. Long-Term Oral Administration. The Journal of Clinical Pharmacology, 1977. 17(8-9): p. 495-500. 83.Kangas, L. and D.D. Breimer, Clinical Pharmacokinetics of Nitrazepam. Clinical Pharmacokinetics, 1981. 6(5): p. 346-366. 84.Meyer, F.P., Indicative therapeutic and toxic drug concentrations in plasma: a tabulation. Int J Clin Pharmacol Ther, 1994. 32(2): p. 71-81. 85.Pan, R.N., et al., Simultaneous determination of triazolam and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2008. 872(1-2): p. 58-62. 86.Gheldiu, A.-M., Popa, A., Neag, M., Muntean, D., Bocsan, C., Buzoianu, A., Vlase, L., Achim, M., Todor, I., & Briciu, C., Assessment of fluvoxamine effects on the pharmacokinetics of zolpidem and its metabolite in healthy volunteers. Farmacia, 2015. 63(3): p. 453-459. 87.Ishida, M., et al., Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol, 1995. 10(3): p. 143-6. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85361 | - |
| dc.description.abstract | 自殺是全球重要的社會公共議題與醫學議題,自殺是台灣第十一大死因,藥毒物是台灣自傷及企圖自殺者最常使用的方式,但此族群的背景及藥物種類尚未被研究。急診室是自殺行為者第一個尋求協助的醫療單位,辨識毒藥物種類及濃度有助於中毒判斷及死因確立,液相層析質譜儀已普遍運用在臨床及法醫毒藥物鑑別實務,但常見自殺藥物之定量方法仍尚未開發。此篇研究目的為探討急診室中不當使用藥物自殺行為者之臨床特性,以及利用液相層析質譜儀定量常見自殺藥物濃度。本研究使用國際診斷分類編碼,篩選出2017年11月至2021年5月台大醫院急診室使用藥物參與自殺行為之病患,統計其基本資料、生理與心理疾病史、藥物濫用史、檢驗報告、會診紀錄,以及使用之藥物種類。研究發現有生理與心理疾病史、過去自殺史,及目前失眠困擾者占研究族群的多數,自殺原因以健康問題為主,住院比例為16.5%,加護病房住院率為0.8%,死亡率0%。在自殺行為中,精神科藥物最常被使用,其中又以苯二氮平類最常見。本研究利用液相層析質譜儀開發血漿中常見自殺藥物的定量方法,並進行方法確效,進一步應用於實際案例。本文之病歷研究限制為病歷數較少及有資料遺漏,實驗限制為儀器測量極限、藥物間可能的訊號干擾以及藥物種類限制,未來期許能在使用藥物的自殺行為者之年齡層或性別上有更詳細的研究,並希望有其他檢測方法彌補液相層析質譜儀的偵測缺點。 | zh_TW |
| dc.description.abstract | Suicide is a serious global public health and medical issue. In Taiwan, suicide is the eleventh cause of death. Self-poisoning by liquid or solid substances is the most common method used by suicide attempters. However, the characteristics of self-poisoners and the substances ingested have not been clarified. The purpose of this study is to interpret the characteristics of drug misusers involved in suicide behaviors and to establish multiple-drugs detection methods by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Suicidal patients involved in drugs were enrolled at the emergency department of National Taiwan University Hospital by the International Classification of Disease-Clinical Modification (ICD-CM). The electronic medical records were collected from November 2017 to May 2021. Females, aged 20-29, single, and individuals who were university-educated and blue-collared were the main demographics in our study population. More than a half of the participants had a history of psychiatric diseases, physical diseases, suicide attempts, or current insomnia. Health problems were the major suicide motive. The admission rate was 16.5%, the ICU admission rate was 0.8% and the mortality rate was 0%. Psychotropics, benzodiazepine in particular, was the most common drug used in suicide behaviors. Sixty-nine medications and twenty metabolites commonly used in suicide behaviors were determined through three LC-MS/MS methods. The methods were validated and applied. Due to limited information on medical records and the difficulties of multiple drug detection by LC-MS/MS, further studies are needed to understand the drugs used among various age and sex groups and more methods should be sought to complement the limitation of LC-MS/MS. | en |
| dc.description.provenance | Made available in DSpace on 2023-03-19T23:00:15Z (GMT). No. of bitstreams: 1 U0001-2107202203131000.pdf: 2675310 bytes, checksum: ff7a848709af7a3df1e7aa0f96ab8a1d (MD5) Previous issue date: 2022 | en |
| dc.description.tableofcontents | Contents 國立臺灣大學碩士學位論文 口試委員會審定書 I 致謝 II 中文摘要 III Abstract IV Contents V Figures VII Tables VII Equations VIII Terminology IX Chapter 1 Introduction 1 1.1. The Epidemiology of Suicide 1 1.2. Risk Factors for Suicide 1 1.3. Characteristics of Drugs Involved in Suicide Behavior 3 1.4. Suicide, Emergency Department and Forensic Medicine 3 1.5. Detection of Suicidal Drugs 4 1.6. Study Purpose 5 Chapter 2 Materials and Methods 6 2.1. Characteristics of Suicidal Patients Involved with Drugs 6 2.2. Suicidal Medications Analysis 8 2.2.1. Chemicals and Materials 8 2.2.2. Preparation of Solutions 8 2.2.3. Sample Preparation 9 2.2.4. Liquid Chromatography 10 2.2.5. Mass Spectrometry 11 2.2.6. Method Development and Validation 11 2.2.6.1. Matrix Effect and Extraction Recovery 12 2.2.6.2. Selectivity 12 2.2.6.3. Linearity and Calibration Curve 13 2.2.6.4. Accuracy and Precision 13 2.2.6.5. Limit of Detection and Limit of Quantification 13 Chapter 3 Results 14 3.1. Characteristics of Suicidal Patients Involved with Drugs 14 3.1.1. Demographic Data 14 3.1.2. Factors of Suicidal Patients Involved with Drugs 15 3.1.3. Suicidal Motive 16 3.1.4. Outcomes of Suicidal Patients Involved with Drugs 16 3.1.5. Characteristics of Drugs Involved in Suicide 17 3.1.6. Screening for Drugs Involved in Suicide Behavior 18 3.2. Analysis of Drugs Involved in Suicide Behavior 20 3.2.1. Method Development 20 3.2.2. Method Validation 21 3.2.2.1. Matrix Effect and Recovery 21 3.2.2.2. Selectivity 22 3.2.2.3. Linearity and Calibration Curve 22 3.2.2.4. Accuracy and Precision 23 3.2.2.5. Limit of Detection and Limit of Quantification 23 3.2.3. Application 24 Chapter 4 Discussion 25 4.1. Characteristics of Suicidal Patients Involved with Drugs 25 4.1.1. Features of Patients 25 4.1.2. Factors of Suicidal Patients Involved with Drugs 26 4.1.3. Suicidal Motive of Suicidal Patients Involved with Drugs 27 4.1.4. Outcomes of Suicidal Patients Involved with Drugs 27 4.1.5. Drugs Involved in Suicide Behavior 27 4.2. Suicidal Medications Analysis by LC-MS/MS 29 4.2.1. Solution of Matrix Effect 29 4.2.2. Limit of Quantification and Drug Identification 29 4.2.3. Blood Concentration Exceeding the Calibration Curve 30 4.3. Limitation 31 Chapter 5 Conclusion 32 References 69 Supplementary 75 Figures Figure 1. Flow chart of the study design to recruit the suicidal patients involved with drugs. 33 Figure 2. Chromatograms of analytes for method 1, 2 and 3 in blank plasma. The numbers above the peaks correspond to the ID number shown in Table 2. 34 Tables Table 1. ICD-10-CM codes for identifying suicide and intentional self-harm 35 Table 2. Transition, declustering potential (DP), entrance potential (EP), collision energy (CE) and cell exit potential (CXP), internal standard (IS) and retention time (RT) for the common suicidal drugs analyzed in plasma using ionization polarity (ESI) in positive mode in method 1 and method 2. 36 Table 3. Transition, declustering potential (DP), entrance potential (EP), collision energy (CE) and cell exit potential (CXP), internal standard (IS) and retention time (RT) for the common suicidal drugs analyzed in plasma using ionization polarity (ESI) in positive mode in method 3. 37 Table 4. Analytical setups, including extraction method, column, mobile phase, gradient, flow rate, and injection volume. 43 Table 5. Demographic characteristics of suicidal patients involved with drugs 44 Table 6. Factors of suicide patients involved with drugs 45 Table 7. Suicide motives 47 Table 8. Outcomes of suicidal patients involved with drugs 47 Table 9. Types of drugs involved in suicide 48 Table 10. Types of psychotropics involved in suicide 49 Table 11. Types and numbers of medications involved in suicide 51 Table 12. Urine drug screening test from 02/2018 to 05/2021 52 Table 13. Urine drug analysis with LC-MS/MS in 30 patients from 01/2020 to 05/20215 (a total of 123 drugs and metabolites) 53 Table 14. Number of medications not detected after urine tests (through screening or LC-MS/MS) in 102 patients 55 Table 15. The analytes and possibly interfering compounds (within ± 0.5amu and 0.2 min retention time. 57 Table 16. Matric effect, extraction recovery, intra- and inter-day precision and accuracy for method 1 and method 2 in plasma. 58 Table 17. Plasma concentration, calibration range, linearity, limit of detection (LOD), limit of quantification (LOQ) for method 1 and method 2 analyzed in plasma. 60 Table 18. Matrix effect and extraction recovery of method 3 in plasma. 61 Table 19. Therapeutic ranges, calibration range, linearity, limit of detection (LOD), and limit of quantification (LOQ) of method 3 in plasma. 63 Table 20. Intra-day accuracy and precision in 36 psychiatric compounds of method 3 in plasma. 66 Table 21. Application of method 1 and method 2. Plasma concentrations of amlodipine, bisoprolol, and metformin in patient 1. 68 Table 22. Application of method 3. Plasma concentrations of bupropion and hydroxybupropion in patient 2. 68 Equations Equation 1. Matrix effect 68 Equation 2. Extraction recovery 68 | |
| dc.language.iso | en | |
| dc.subject | 企圖自殺 | zh_TW |
| dc.subject | 液相層析質譜儀 | zh_TW |
| dc.subject | 藥物自殺 | zh_TW |
| dc.subject | 自殺行為 | zh_TW |
| dc.subject | 服藥自殺 | zh_TW |
| dc.subject | 藥物不當使用 | zh_TW |
| dc.subject | suicide behavior | en |
| dc.subject | self-poisoning | en |
| dc.subject | drug misuse | en |
| dc.subject | suicide attempt | en |
| dc.subject | liquid chromatography-tandem mass spectrometry | en |
| dc.subject | deliberate drug poisoning | en |
| dc.title | 急診室不當使用藥物自殺行為之臨床特性探討及利用液相層析質譜儀定量常見自殺藥物濃度 | zh_TW |
| dc.title | Characteristics of Suicide Behaviors Due to Drug Misuse Confirmed by Liquid Chromatography-Tandem Mass Spectrometry at the Emergency Department | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 110-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 陳冠元(Guan-Yuan Chen) | |
| dc.contributor.oralexamcommittee | 陳亮妤(Lian-Yu Chen) | |
| dc.subject.keyword | 自殺行為,企圖自殺,藥物不當使用,服藥自殺,藥物自殺,液相層析質譜儀, | zh_TW |
| dc.subject.keyword | suicide behavior,suicide attempt,drug misuse,self-poisoning,deliberate drug poisoning,liquid chromatography-tandem mass spectrometry, | en |
| dc.relation.page | 84 | |
| dc.identifier.doi | 10.6342/NTU202201593 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2022-07-22 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 法醫學研究所 | zh_TW |
| dc.date.embargo-lift | 2022-10-03 | - |
| 顯示於系所單位: | 法醫學科所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-2107202203131000.pdf 授權僅限NTU校內IP使用(校園外請利用VPN校外連線服務) | 2.61 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
